Who we are

Delivering on our promise for patients

Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics to fight against cancer and other serious diseases.

An experienced international management team sets the direction for our growth. Our proprietary product pipeline and next-generation antibody technologies result from a strong company culture and passion for innovation. We are rooted in science and inspired by patients.

OUR GENMAB 2030 VISION

Our employees share their perspective on what Genmab’s 2030 vision means to them, as well as our passion for creating knock-your-socks-off (KYSO®) antibodies.

Genmab

OUR PURPOSE

Combating cancer and other serious diseases through the power of antibodies

Our core purpose summarizes what we strive for – our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics. It supports our vision which captures our aspirations for our future – that by 2030, our knock-your-socks-off antibody medicines (KYSO antibody medicines®) are transforming the lives of people with cancer and other serious diseases.

UNLEASHING THE FULL POTENTIAL OF OUR INNOVATIONS

Hear from Genmab’s President and CEO Jan G. J. van de Winkel, Ph.D. how our inspirational 2030 vision came to life. Take a look at the video to learn more.


Our core values

In our quest to turn science into medicine, we use these guideposts to transform the future of cancer treatment:  

  • Passion for innovation
  • Determination—being the best at what we do
  • Integrity—we do the right thing
  • We work as one team and respect each other


Our key accomplishments

Each of our achievements stands as evidence of our unyielding determination, including:

  • 8 Approved therapies incorporating Genmab innovation*
  • Inventors of four proprietary technologies
  • Growing multiple proprietary clinical programs
  • Pioneers of a robust pre-clinical pipeline
  • World-class leaders with antibody and R&D expertise
  • Partners of choice with strategic collaborations
  • Solid financials
  • Building and expanding our capabilities with more than 2,000 employees across our four international locations

Use our Investor’s Fact Sheet to get a snapshot of our achievements, our process and our financials. 

2 therapies co-marketed by Genmab and partners, 6 out-licensed products marketed by partners

  • Join our mission

    Be a part of our team and help transform the future of cancer treatment

    Learn more

  • Turning insights into medicine

    See the results of innovation that is rooted in science

    Explore the pipeline

  • Putting our expertise to work

    See how we put our in-depth knowledge of antibody biology into action

    Learn about our science

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.

Continue

Back